Versant Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Versant Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20K	Buy	2,003 +1,521	+316%	+$13.8K	﹤0.01%	1928
2026 Q1	$4.59K	Buy	482 +328	+213%	+$2.55K	﹤0.01%	2406
2025 Q4	$1.2K	Hold	154	–	–	﹤0.01%	2513
2025 Q3	$1.17K	Hold	154	–	–	﹤0.01%	2483
2025 Q2	$1.38K	Buy	+154	New	+$1.43K	﹤0.01%	2448
2023 Q3	–	Sell	-59	Closed	-$415	–	1948
2023 Q2	$415	Buy	+59	New	+$473	﹤0.01%	1873

Other funds holding BCRX

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Cypress Wealth Services Palm Desert, California $813M AUM 27.86% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.8B AUM 48.92% 1-Year Est. Return

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Independence Bank of Kentucky Owensboro, Kentucky $888M AUM 29.17% 1-Year Est. Return

Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return